Intractable Rare Dis Res. 2016;5(3):158-167. (DOI: 10.5582/irdr.2016.01045)

Review of targeted treatments in fragile X syndrome.

Ligsay A, Hagerman RJ


Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well.

KEYWORDS: Fragile X syndrome, targeted treatments, clinical trial

Full Text: